article thumbnail

Dermatology program brings timely and accurate diagnosis of skin conditions to underserved communities

Medical Xpress

A dermatology program first developed by the University of Missouri in 2015 can bring life-saving diagnoses of skin conditions to communities without adequate dermatologic care.

article thumbnail

Fishawack Health welcomes expert-led dermatology initiative FIDE to its group

pharmaphorum

KNUTSFORD, United Kingdom — Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology. FIDE’s global healthcare experts provide biopharmaceutical companies with unique insights from early phase research to real-world evidence post-approval.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Internship Program Boosts Clinical Research Workforce Development in Pennsylvania

ACRP blog

Lessons learned from a new clinical research internship program held in central Pennsylvania last summer have helped prepare new and upcoming entrants for the research workforce, as well as to inform how the next generation of the program will evolve. alongside the Milton S. alongside the Milton S.

article thumbnail

Researchers design genetic therapy to prevent brain deterioration

Drug Discovery World

A research team at the Francis Crick Institute and Great Ormond Street Hospital (GOSH)/UCL Great Ormond Street Institute of Child Health have identified potential treatments for children with rare genetic conditions. The researchers have shown that problems with calcium underlie these progressive diseases.

article thumbnail

KFA-115 by Novartis for Melanoma: Likelihood of Approval

Pharmaceutical Technology

It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz.

article thumbnail

Incannex engages QPS for CannQuit and ReneCann

Pharmaceutical Technology

QPS is preparing the pre-investigational new drug applications to be submitted to the US Food and Drug Administration (FDA) and the EU’s European Medicines Agency (EMA) for the CannQuit and ReneCann products. In 2022, the company acquired CannQuit and ReneCann products as part of the acquisition of APIRx Pharmaceuticals.

article thumbnail

Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata

The Pharma Data

Data support baricitinib’s ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA). . The data underscore Lilly’s commitment to providing medicines for dermatologic diseases that have high unmet need, including alopecia areata (AA). INDIANAPOLIS , Oct.